LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA– FINAL ANALYSIS AT 2-YEAR FOLLOW-UP

EHA Library, Philippe Moreau, 386733

GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A

EHA Library, Paula Rodríguez-Otero, 386735

EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3

EHA Library, Cyrille Touzeau, 386736

IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A

EHA Library, Katja Weisel, 386737

POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE CHEMOTHERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: POMACE PHASE II STUDY

EHA Library, Fen Saj, 386738

DISPARATE PREDICTION OF OUTCOMES IN A UNIFORMLY TREATED COHORT OF PATIENTS WITH AL AMYLOIDOSIS STRATIFIED BY MAYO 2012 AND EUROPEAN CARDIAC STAGING SYSTEMS

EHA Library, Jahanzaib Khwaja, 386739

ADDING REFRACTORINESS STATUS TO LINES OF THERAPY BETTER DEFINE PROGNOSIS OF A REAL LIFE ITALIAN MULTIPLE MYELOMA POPULATION

EHA Library, Sonia More', 386741

LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM-5 PLATFORM SUB-STUDY 3

EHA Library, Sebastian Grosicki, 386742

VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY

EHA Library, Iuliana Vaxman, 386743

TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY

EHA Library, Rafat Abonour, 386744

SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES

EHA Library, María-Victoria Mateos, 386746

ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL

EHA Library, Claudio Cerchione, 386747

TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.

EHA Library, Thomas Lund, 386748

EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA STUDY GROUP EXPERIENCE.

EHA Library, Eirini Katodritou, 386749

ARTIFICIAL INTELLIGENCE BASED FDG PET/CT RADIOMICS FOR RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Jacob Shreve, 386750

ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY

EHA Library, María-Victoria Mateos, 386751

COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Hermann Einsele, 386752

TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A REAL-WORLD OBSERVATIONAL CHART REVIEW STUDY

EHA Library, Ravi K Goyal, 386753

PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA

EHA Library, Wenming Chen, 386754

ELEVATED SERUM LEVELS OF SOLUBLE B-CELL MATURATION ANTIGEN AS A PROGNOSTIC BIOMARKER FOR MULTIPLE MYELOMA

EHA Library, Juan Du, 386755

ACTUAL USAGE OF CURRENT SYSTEMIC TREATMENTS AND INFLUENCE OF KEY DRIVERS FOR MULTIPLE MYELOMA IN THE FIRST 2 LINES OF THERAPY. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES.

EHA Library, Nicolas Blin, 386756

OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

EHA Library, Evangelos Terpos, 386757

CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE

EHA Library, Yasunori Kogure, 386758

ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2

EHA Library, Xavier Leleu, 386759

ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS

EHA Library, Philippe Moreau, 386760

INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

EHA Library, Patrick Hlavacek, 386762

THE EFFECTS OF EXTRAMEDULLARY DISEASE ON OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Yi Tao, 386763

EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA

EHA Library, Wenqiang Yan, 386764

EXPLORING HETEROGENEITY IN TREATMENT PREFERENCES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES, UNITED KINGDOM, FRANCE, SPAIN, ITALY AND GERMANY

EHA Library, Rakesh Popat, 386765

CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP.

EHA Library, Antonio Garcia-Guiñon, 386766

SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA IN THE GENERAL POPULATION BASED ON DATA FROM TWO FRENCH CANCER REGISTRIES

EHA Library, Hakima Mechiche, 386767

THE RELATIONSHIP OF BONE MARROW FIBROSIS WITH EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA

EHA Library, Hilal Konyaoglu, 386768

AN OUTPATIENT MODEL FOR TECLISTAMAB STEP-UP DOSING ADMINISTRATION – INITIAL EXPERIENCES AT FOX CHASE CANCER CENTER BMT PROGRAM.

EHA Library, Asya Nina Varshavsky-Yanovsky, 386769

SERUM CXCL13 LEVEL AIDS IN DISEASE REMISSION EVALUATION AND PROGNOSIS PREDICTION IN WALDENSTRÖM MACROGLOBULINEMIA

EHA Library, JIA CHEN, 386770

MULTIPLE MYELOMA OLIGOSECRETORY RELAPSE- A CROSS SECTIONAL HISTORICAL COHORT STUDY

EHA Library, Yael Cohen, 386771

OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM-02)

EHA Library, Heinz Ludwig, 386772

REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK

EHA Library, Ivan Spicka, 386773

REAL-WORLD CLINICAL OUTCOMES AMONG TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY

EHA Library, Hartmut Goldschmidt, 386774

TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB

EHA Library, María-Victoria Mateos, 386775

TREATMENT PATTERNS AND OUTCOMES OF RE-INDUCTION THERAPIES PRIOR TO STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED IN CLINICAL PRACTICE IN GERMANY

EHA Library, Sandra Sauer, 386776

REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA

EHA Library, Maria Nieves Lopez Muñoz, 386777

COMBINATION GA AND MPR VULNERABILITY SCORING TOOLS EFFECTIVELY IMPROVE THE ABILITY TO IDENTIFY THE FRAIL ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Li Bao, 386778

PRIOR CANCER AND RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS): A POPULATION-BASED STUDY IN ICELAND AND SWEDEN

EHA Library, Sæmundur Rögnvaldsson, 386779

IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)

EHA Library, Bruno Paiva, 386780

PROGNOSTIC SIGNIFICANCE OF DYNAMIC CHANGE OF MAGE-C1/CT7 IN MULTIPLE MYELOMA: TEN YEAR EXPERIENCE FROM A SINGLE CENTER

EHA Library, Xuelin Dou, 386781

ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL

EHA Library, Claudio Cerchione, 386782

MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY

EHA Library, Vania Hungria, 386783

BURDEN OF INFECTION IN PATIENTS WITH MULTIPLE MYELOMA AND SECONDARY IMMUNODEFICIENCIES: A RETROSPECTIVE COHORT STUDY

EHA Library, Joshua Richter, 386784

VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN  A REAL WORLD COHORT:  AN ANALYSIS BY THE BALKAN MYELOMA STUDY GROUP (BMSG)

EHA Library, Efstathios Kastritis, 386785

AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)

EHA Library, Luciano Costa, 386786

REAL-WORLD TREATMENT PATTERNS IN PATIENTS INITIATING THIRD-LINE THERAPY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN GERMANY, ITALY, THE UK, FRANCE, AND SPAIN

EHA Library, Karthik Ramasamy, 386787

MAINTENANCE THERAPY FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANTATION BY IXAZOMIB AND/OR LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A MULTICENTERED REAL WORLD STUDY IN CHINA

EHA Library, Li Bao, 386788

EXTRAMEDULLARY MYELOMA REMAINS AN UNMET CLINICAL NEED EVEN IN THE ERA OF NOVEL AGENT. ANALYSIS OF THE SINGLE CENTER MCOHORT.

EHA Library, Annamaria Brioli, 386789

BORTEZOMIB, RITUXIMAB AND DEXAMETHASONE REGIMEN (BDR) IN WALDENSTRÖM MACROGLOBULINEMIA: A RETROSPECTIVE ANALYSIS

EHA Library, thomas Hueso, 386790

COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.

EHA Library, Ross Firestone, 386791

EXTRAMEDULLARY MULTIPLE MYELOMA: CLINICAL CHARACTERISTICS, IMPACT, AND OUTCOMES IN A COHORT OF PATIENTS IN MEXICO

EHA Library, Amaya Llorente Chávez, 386792

STEM-CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE 4 G/M2 ALLOWS COLLECTION OF HIGH NUMBERS OF CD34+ CELLS AFTER DARA-VTD INDUCTION FOR MULTIPLE MYELOMA

EHA Library, Francesca Farina, 386794

SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIVE MM DURING FOLLOW-UP: REDUCED BONE DISEASE AND IMPROVED PROGRESSION-FREE AND OVERALL SURVIVAL COMPARED TO DE-NOVO NEWLY DIAGNOSED MM

EHA Library, Yael Cohen, 386795

A MACHINE LEARNING MODEL FOR RISK PREDICTION IN MULTIPLE MYELOMA PROGRESSING AFTER THE FIRST LINE OF THERAPY

EHA Library, Adrian Mosquera-Orgueira, 386796

ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES

EHA Library, Aurore Perrot, 386797

VRD OUTPERFORMED VCD AS INDUCTION THERAPY BEFORE FIRST-LINE ASCT IN MULITPLE MYELOMA; RESULTS FROM A NATIONWIDE, POPULATION-BASED STUDY

EHA Library, Jakob Nordberg Nørgaard, 386798

A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE

EHA Library, Anna Furlan, 386799

EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.

EHA Library, Francesca Fazio, 386800

RISK-BENEFIT RATIO OF PERCUTANEOUS KYPHOPLASTY AND PERCUTANEOUS VERTEBROPLASTY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WITH VERTEBRAL FRACTURE: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Li Bao, 386801

ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE

EHA Library, Sonia More', 386802

INTERIM ANALYSIS OF THE LAUNCH STUDY-A MULTICENTER, OPEN-LABEL STUDY OF SELINEXOR, DEXAMETHASONE PLUS CHEMOTHERAPY DRUGS IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA

EHA Library, Chunyan Sun, 386803

THREE-DIMENSIONAL TELOMERE PROFILING PREDICTS RISK OF RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Shaji Kumar, 386804

REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS

EHA Library, Jun Ho Yi, 386805

THE VENOUS THROMBOEMBOLISM RISK ASSESMENT MODELS IN MULTIPLE MYELOMA

EHA Library, Tugcan Alp Kirkizlar, 386806

EVOLVING PATTERNS IN MULTIPLE MYELOMA TREATMENT ATTRITION RATES AND PROGRESSION THROUGH LINES OF THERAPY WITH MODERN CHEMOTHERAPY OPTIONS

EHA Library, Firas Al-Kaisi, 386807

PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Philippe Moreau, 386808

THE ROLE OF PLATELET AND ENDOTHELIAL MICROPARTICLES AND DOPPLER ULTRASOUND SCREENING IN THE ASSESSMENT OF THROMBOTIC READINESS IN MULTIPLE MYELOMA AND NON HODGKIN LYMPHOMA, PROSPECTIVE STUDY

EHA Library, Magdalena Olszewska-Szopa, 386809

DISEASE CHARACTERISTICS AND TREATMENT OUTCOMES OF MYELOMA PATIENTS <50 YEARS OF AGE: AN ANALYSIS OF THE BALKAN MYELOMA STUDY GROUP

EHA Library, Efstathios Kastritis, 386810

EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Darrell White, 386811

DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS

EHA Library, Hang Quach, 386812

DIFFERENTIAL IMPACTS OF DISTINCT MUTATION SUBTYPES ON ALTERED S100A8 EXPRESSION AND PHENOTYPIC HETEROGENEITY IN CALR-MUTANT MPN

EHA Library, Ying-Ju Chen, 386813

CLL-1 IS AN ADOPTIVE IMMUNOTHERAPY TARGET IN JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Juwita Huebner, 386814

COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Zachary Zaroogian, 386815

IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL

EHA Library, Ernesto José Cuenca Zamora, 386816

MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Kristin Holl, 386817

NEWLY IDENTIFIED ROLES FOR PIEZO1 MECHANOSENSOR IN CONTROLLING NORMAL MEGAKARYOCYTE DEVELOPMENT AND IN PRIMARY MYELOFIBROSIS

EHA Library, Vittorio Abbonante, 386818

NF-ΚB AND JAK/STAT PATHWAYS INHIBITION REVERSES FIBROSIS IN A MURINE MODEL OF INFLAMMATION-DRIVEN MYELOFIBROSIS

EHA Library, Ernesto José Cuenca Zamora, 386819

ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

EHA Library, Tracy Clevenger, 386820

A MODIFIED ACTIVIN RECEPTOR TYPE II LIGAND TRAP RKER-050 RESTORED ERYTHROPOIESIS IN A MOUSE MODEL OF MYELOFIBROSIS

EHA Library, Blake Moses, 386821

INCREASED STAT5B LEVELS IN MYELOPROLIFERATIVE NEOPLASMS LEAD TO ENHANCED MEGAKARYOCYTIC DIFFERENTIATION CORRELATING WITH THROMBOSIS

EHA Library, Marie Ploderer, 386822

GERMLINE SINGLE-NUCLEOTIDE VARIANTS (SNV) IN THE JAK-STAT PATHWAY GENOME OF ADOLESCENT AND YOUNG ADULTS (AYA) AND NON-AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)

EHA Library, Alice Diepers, 386823

INDEED: A DEEP LEARNING MODEL FOR DIAGNOSIS AND SUBTYPES DIFFERENTIATION OF MYELOPROLIFERATIVE NEOPLASM BASED ON INTELLIGENCE NEURAL NETWORK

EHA Library, Rong Wang, 386824

A NOVEL GERMLINE GAIN-OF-FUNCTION JAK2 MUTATION: L604F

EHA Library, Lukas Dvoracek, 386825

FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS

EHA Library, Vikas Gupta, 386826

TRETINOIN AND CALCITRIOL ENHANCE TREATMENT REGIMENS FOR JUVENILE MYELOMONOCYTIC LEUKEMIA IN EX VIVO DRUG SENSITIVITY ASSAYS

EHA Library, Elliot Stieglitz, 386827

ROLE OF GENETIC VARIANTS IN PREDICTING EFFICACY AND/OR ADVERSE EVENTS OF ROPEGINTERFERON ALPHA-2B IN MPN PATIENTS: A RETROSPECTIVE ANALYSIS FROM AN ASIAN COHORT

EHA Library, Chih-Cheng Chen, 386828

GENOMIC AND TRANSCRIPTOMIC PROFILING REVEALS NOVEL GENE FUSIONS AND MARKERS OF CLINICAL RESPONSE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Borbála Péterffy, 386829

GENOMIC CHARACTERIZATION OF CHILDHOOD B-OTHER ACUTE LEUKEMIA PATIENTS BY RNA SEQUENCING IN A SINGLE CENTER

EHA Library, Clara Vicente Garcés, 386830

REPLACING THE CURRENT METHODS IN LEUKEMIA DIAGNOSTICS WITH OPTICAL GENOME MAPPING AND CAS9-DIRECTED NANOPORE SEQUENCING.

EHA Library, Sabrina Commandeur-Jan, 386831

ACTIVINA MODULATES THE MICRORNA CARGO OF EXTRACELLULAR VESICLES RELEASED BY  B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) CELLS

EHA Library, Eugenia Licari, 386832

A NOVEL APPROACH OF DUAL METAGENOMICS NEXT-GENERATION SEQUENCING FOR EARLY DIAGNOSIS OF BLOOD STREAM INFECTION IN HEMATOLOGIC PATIENTS WITH FEBRILE NEUTROPENIA: A MULTICENTER, PROSPECTIVE STUDY

EHA Library, Yuqian Sun, 387993

MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.

EHA Library, Rafael F Duarte, 387994

TACROLIMUS MODULATES CD4+ T-CELL PROLIFERATION AND FUNCTION VIA MTHFD2 IN IMMUNE THROMBOCYTOPENIA

EHA Library, Li-Ping Yang, 387995

IL-1Β SIGNALLING INDUCES, AND BARICITINIB ALLEVIATES NEU1-MEDIATED MEGAKARYOCYTE DESIALYLATION IN IMMUNE THROMBOCYTOPENIA

EHA Library, Peng Zhao, 387996

CANCER RISK IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA – A DANISH NATIONWIDE COHORT STUDY

EHA Library, Nikolaj Mannering, 387997